The use of antiviral Phthalocyanine mouthwash as a preventive measure against COVID-19

Vilhena, Fabiano Vieira; Reia, Verônica Caroline Brito; Orcina, Bernardo da Fonseca; Santos, Cleusa Lapa; Zangrando, Mariana Schützer Ragghianti; Oliveira, René R.; Santos, Paulo Sérgio da Silva

doi:10.3205/dgkh000395

Cited by 8 publications

(10 citation statements)

References 7 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The prevalence of symptoms was examined at baseline (T0), 3 (T3), and 7 (T7) days after using APD in oral hygiene products and compared to the control group. These results are in accordance with clinical and laboratory evidence built over this pandemic period on the beneficial effect of using APD in oral care products against COVID-19 in the studies samples 14 , 15 , 16 , 20 , 21 , 22 , 23 .…”

Section: Discussionsupporting

confidence: 89%

“…There was a significant reduction in six self-reported symptoms in the control group during the follow-up period and a significant improvement (P<0.05) in all major COVID-19 symptoms in the APD group ( Table 3 ). Both groups presented with symptom reduction; however, the APD group showed a significant reduction during the follow-up period (94.9–49.2%, Table 4 ) and these results may be related to the mechanical, antimicrobial, anti-inflammatory, and tissue regeneration actions 15 , 16 , 20 , 21 , 22 , 23 . Based on these studies, we did not include a placebo group in this study because the timing of the pandemic required a clinical study to provide direct benefits to all the research participants.…”

Section: Discussionmentioning

confidence: 96%

“…In the pandemic context, few oral antimicrobial products have been investigated for the maintenance of oral hygiene and as a measure to prevent COVID-19, especially those containing chlorhexidine, hydrogen peroxide, povidone-iodine, and, more recently, an antimicrobial phthalocyanine derivative (APD) 19 , 20 . Phthalocyanine derivative is a compound with oxidizing properties, with principle of promoting self-activation and continues production of reactive oxygen in the presence of molecular oxygen.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Use of Mouthwash and Dentifrice Containing an Antimicrobial Phthalocyanine Derivative for the Reduction of Clinical Symptoms of Covid-19: A Randomized Triple-Blind Clinical Trial

Poleti

Gregorio²,

Bistaffa³

et al. 2022

Journal of Evidence-Based Dental Practice

Self Cite

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 89%

Section: Discussionmentioning

confidence: 96%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Use of Mouthwash and Dentifrice Containing an Antimicrobial Phthalocyanine Derivative for the Reduction of Clinical Symptoms of Covid-19: A Randomized Triple-Blind Clinical Trial

Poleti

Gregorio²,

Bistaffa³

et al. 2022

Journal of Evidence-Based Dental Practice

Self Cite

View full text Add to dashboard Cite

“…With the progress of the COVID-19 pandemic, we can highlight the importance of materials science, in the search for new tools and technologies for antiviral research and treatment development 18 . Among the new tools to treat patients with COVID-19 is the development of a phthalocyanine-derived mouthwash that appears as a promising alternative for reducing the viral load of SARS-CoV-2 and the clinical improvement of infected patients who presented moderate symptoms 19 , 20 . Phthalocyanines (Pc) are chemical compounds with applications in various technological systems, such as pigments 21 , catalysts 22 – 24 , biosensors 25 , 26 , chemical sensors 27 , dyes 28 , and photodynamic therapy (PDT) 29 – 32 , because of its various electronic and optical properties 33 .…”

Section: Introductionmentioning

confidence: 99%

Interactions of Co, Cu, and non-metal phthalocyanines with external structures of SARS-CoV-2 using docking and molecular dynamics

Alencar

Arouche

Neto

et al. 2022

Sci Rep

View full text Add to dashboard Cite

The new coronavirus, SARS-CoV-2, caused the COVID-19 pandemic, characterized by its high rate of contamination, propagation capacity, and lethality rate. In this work, we approach the use of phthalocyanines as an inhibitor of SARS-CoV-2, as they present several interactive properties of the phthalocyanines (Pc) of Cobalt (CoPc), Copper (CuPc) and without a metal group (NoPc) can interact with SARS-CoV-2, showing potential be used as filtering by adsorption on paints on walls, masks, clothes, and air conditioning filters. Molecular modeling techniques through Molecular Docking and Molecular Dynamics were used, where the target was the external structures of the virus, but specifically the envelope protein, main protease, and Spike glycoprotein proteases. Using the g_MM-GBSA module and with it, the molecular docking studies show that the ligands have interaction characteristics capable of adsorbing the structures. Molecular dynamics provided information on the root-mean-square deviation of the atomic positions provided values between 1 and 2.5. The generalized Born implicit solvation model, Gibbs free energy, and solvent accessible surface area approach were used. Among the results obtained through molecular dynamics, it was noticed that interactions occur since Pc could bind to residues of the active site of macromolecules, demonstrating good interactions; in particular with CoPc. Molecular couplings and free energy showed that S-gly active site residues interacted strongly with phthalocyanines with values of − 182.443 kJ/mol (CoPc), 158.954 kJ/mol (CuPc), and − 129.963 kJ/mol (NoPc). The interactions of Pc's with SARS-CoV-2 may predict some promising candidates for antagonists to the virus, which if confirmed through experimental approaches, may contribute to resolving the global crisis of the COVID-19 pandemic.

show abstract

“…Diante do SARS-CoV-2, em testes in vitro, um enxaguatório bucal contendo ftalocianina em uma concentração de 0,015% apresentou inativação de 90% do vírus (62). Já quando essa concentração foi aumentada para 0,02% e realizado o mesmo teste houve inibição de 99,9% deste vírus (63). Na realização de testes in vitro com enxaguatório bucal a uma concentração de 0,015% de ftalocianina, porém com os microorganismos Escherichia coli,…”

Section: Aos Queridos Funcionáriosunclassified

Avaliação da eficácia de um antisséptico oral contendo derivado de ftalocianina de ferro na melhora do quadro clínico, diminuição da carga viral e tempo de internação em pacientes com a COVID-19

Orcina¹

View full text Add to dashboard Cite

Evaluation of the efficacy of an oral antiseptic containing an iron phthalocyanine derivative in improving the clinical picture, decreasing viral load and length of hospital stay in patients with COVID-19The following master's thesis is made up of two scientific articles chosen from the approved research project for this purpose. The first article is a series of 11 patients who were admitted to the hospital and had COVID-19 confirmed by RT-PCR. They were told to use an oral spray containing a phthalocyanine derivative, and the posology was three sprays in each region of the mouth: throat, tongue, and jugal mucosa bilaterally. Still, after spraying, alternate between mouth rinses and gargling for 30 seconds, 5 times per day (after waking up, after breakfast, lunch, dinner and before bed). Furthermore, salivary samples were collected before the patients used the product, as well as 2 and 4 days later, and were tested for SARS-CoV-2 positivity or negativity using RT-PCR. As a result, 48 hours after using the product, 5 patients had negative RT-PCR for salivary samples; 96 hours later, 4 of them had already been discharged from the hospital, and 4 other patients had negative samples. In the second article, a triple-blind randomized clinical trial was conducted with patients who were also COVID-19 positive, as determined by RT-PCR, and were hospitalized. The randomly assigned groups used mouthwash that contained or did not contain the same phthalocyanine derivative and were instructed to rinse/gargle 5 ml of the solution for 1 minute during the same 5 moments mentioned above. The variables studied were length of hospital stay, clinical evolution, need for ICU transfer, and death. To compare the means of age, number of comorbidities, and duration of symptoms prior to hospitalization, the non-parametric Mann-Whitney test was used. The Fisher's exact test was used to assess the need for ICU admission and death. The active group (n=20) and the non-active group (n=21) were formed by randomly assigned patients. The latter had a significantly lower mean age than the experimental group (p=0.0069). Furthermore, the experimental group had a shorter length of stay (p0.05) and did not require ICU referral (p0.05). Despite the lack of statistical significance, the placebo group had three deaths while the active group had none. Thus, these findings suggest that phthalocyanine derivativecontaining mouthwash can be used as a therapeutic adjuvant in patients with COVID-19 who are hospitalized. Finally, the use of phthalocyanine derivative-containing oral spray and mouthwash products does not preclude the use of World Health Organization-established COVID-19 medical protocols (WHO).

show abstract

The use of antiviral Phthalocyanine mouthwash as a preventive measure against COVID-19

Cited by 8 publications

References 7 publications

Use of Mouthwash and Dentifrice Containing an Antimicrobial Phthalocyanine Derivative for the Reduction of Clinical Symptoms of Covid-19: A Randomized Triple-Blind Clinical Trial

Use of Mouthwash and Dentifrice Containing an Antimicrobial Phthalocyanine Derivative for the Reduction of Clinical Symptoms of Covid-19: A Randomized Triple-Blind Clinical Trial

Interactions of Co, Cu, and non-metal phthalocyanines with external structures of SARS-CoV-2 using docking and molecular dynamics

Avaliação da eficácia de um antisséptico oral contendo derivado de ftalocianina de ferro na melhora do quadro clínico, diminuição da carga viral e tempo de internação em pacientes com a COVID-19

Contact Info

Product

Resources

About